About this term
- Quick definition
- Transcranial magnetic stimulation. A noninvasive, FDA-cleared treatment that uses focused magnetic pulses to stimulate the brain regions involved in mood regulation. No anesthesia, no sedation, no hospitalization.
- Full clinical definition
- Repetitive TMS (rTMS) for depression delivers magnetic pulses through a coil placed on the scalp over the left dorsolateral prefrontal cortex. The pulses induce small electrical currents in the cortex without surgery or anesthesia. A standard course is daily sessions, five days a week, for four to six weeks (about 30 to 36 sessions). Each session lasts 20 to 40 minutes for standard high-frequency protocols, or as short as three minutes for intermittent theta-burst stimulation (iTBS), which has comparable effectiveness (Blumberger et al., Lancet, 2018).
- Epidemiology and evidence base
- In treatment-resistant depression, response rates are roughly 40 to 60 percent and remission rates are roughly 25 to 40 percent across published trials and naturalistic studies (Carpenter et al., Depress Anxiety, 2012). TMS is generally less effective than ECT for severe depression but more accessible, with no anesthesia and no cognitive side effects. The first device was FDA-cleared for depression in 2008; multiple devices and protocols are now available, including iTBS and accelerated protocols.
- What a course can look like
- A patient with depression that hasn't responded to two antidepressants drives to a TMS clinic five days a week for six weeks. They sit in a reclining chair while the technician positions the coil. The pulses produce a tapping sensation on the scalp and small twitches of the forehead and jaw. They read or listen to music during the session and drive themselves to work afterward. Most patients who respond start to notice change in the second or third week.
- Why it matters
- TMS expanded the options for treatment-resistant depression in a meaningful way, particularly for patients who can't tolerate medications, who don't want ECT, or for whom ECT isn't a fit. Unlike ECT, TMS doesn't affect memory, doesn't require anesthesia, and doesn't interrupt work or daily life.
- How clinicians assess it
- Screening covers the depression history, prior treatments, seizure history, alcohol use, current medications, and metallic implants in or near the head. The first session includes motor threshold determination, in which the technician calibrates pulse intensity to each patient's individual cortical excitability. A response is usually reassessed at four weeks; non-responders may switch to a different protocol or end treatment.
- Treatment implications
- TMS is FDA-cleared for adults with major depressive disorder who haven't responded to at least one antidepressant in the current episode. Most commercial insurers and Medicare cover TMS after one or two failed antidepressant trials, with prior authorization. Side effects are usually mild scalp discomfort and headache that improve in the first week. The most serious risk, seizure, is rare (roughly 1 in 30,000 sessions).
- Related terms
- Treatment-resistant depression. ECT. Ketamine and esketamine. Antidepressant.
- Related articles
- Depression treatment, explained.
Sources
- Carpenter LL, et al. Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice. Depress Anxiety. 2012.
- Blumberger DM, et al. Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. Lancet. 2018.
- Perera T, et al. The Clinical TMS Society consensus review and treatment recommendations for TMS therapy for major depressive disorder. Brain Stimul. 2016.
- Cole EJ, et al. Stanford Neuromodulation Therapy (SNT): a double-blind randomized controlled trial. Am J Psychiatry. 2022.